Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 -0.84%84 Debt-to-EBITDA is 2.33 as of Jun. 2026, which is 49% below its 10-year median of 4.57. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$33.92 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 678 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 65.49% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Synmosa Biopharma's Debt-to-EBITDA or its related term are showing as below:
ROCO:4114'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.09 Med: 4.57 Max: 177.13
Current: 2.8
During the past 13 years, the highest Debt-to-EBITDA Ratio of Synmosa Biopharma was 177.13. The lowest was 2.09. And the median was 4.57.
ROCO:4114's Debt-to-EBITDA is ranked worse than 65.49% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs ROCO:4114: 2.80
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Synmosa Biopharma Debt-to-EBITDA Related Terms
Synmosa Biopharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Synmosa Biopharma (ROCO:4114) has a Debt-to-EBITDA of 2.33 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Synmosa Biopharma. This is 49% below median its historical median of 4.57. Over the past decade, Synmosa Biopharma's Debt-to-EBITDA has ranged from 2.09 to 177.13. According to the industry distribution chart, Synmosa Biopharma ranks #444 out of 678 companies in the Drug Manufacturers industry, placing it in the top 65.5%.
Is Synmosa Biopharma's Debt-to-EBITDA too high?
Synmosa Biopharma's current Debt-to-EBITDA of 2.33 is 49% below median its 10-year median of 4.57. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 177.13. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Synmosa Biopharma's value of 2.33 is 42.1% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #444 out of 678 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #444 out of 678 companies for Debt-to-EBITDA. This places Synmosa Biopharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Synmosa Biopharma's value of 2.33 is 42.1% above this benchmark. Historically, Synmosa Biopharma's own Debt-to-EBITDA has ranged from 2.09 to 177.13 over the past decade. While the company's 10-year median is 4.57 vs. the industry median of 1.64, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current Debt-to-EBITDA of 2.33 is 42.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Synmosa Biopharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current Debt-to-EBITDA is 2.33, which is 49% below median its own 10-year median of 4.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.92, compared to a current price of NT$29.50 — trading 13% below its estimated fair value. The current Debt-to-EBITDA is 2.33, which is 49% below median its 10-year median of 4.57 and 42.1% above the Drug Manufacturers industry median of 1.64. Synmosa Biopharma's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Debt-to-EBITDA is 2.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.50 is trading 13% below its estimated GF Value™ of NT$33.92.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
Debt-to-EBITDA: 2.33 (49% below median its 10-year median of 4.57)
GF Value™: NT$33.92 vs. price of NT$29.50 (13% below fair value)
Industry Position: 42.1% above the Drug Manufacturers median (#444 of 678)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
